|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Epithelial ovarian cancer:An overview显示文摘Ovarian cancer is the second most common gyneco-logical cancer and the leading cause of death in the United States. In this article we review the diagnosis and current management of epithelial ovarian cancer which accounts for over 95 percent of the ovarian malignancies. We will present various theories about the potential origin of ovarian malignancies. We will discuss the genetic anomalies and syndromes that may cause ovarian cancers with emphasis on Breast cancer type 1/2 mutations. The pathology and pathogenesis of ovarian carcinoma will also be presented. Lastly, we provide a comprehensive overview of treatment strategies and staging of ovarian cancer, conclusions and future directions. | Arpita Desai Jingyao Xu Kartik Aysola Yunlong Qin Chika Okoli Ravipati Hariprasad Ugorji Chinemerem Candace Gates Avinash Reddy Omar Danner Geary Franklin Anachebe Ngozi Guilherme Cantuaria Karan Singh William Grizzle Charles Landen Edward E Partridge Valerie Montgomery Rice E Shyam P Reddy Veena N Rao | 2014 | World Journal of Translational Medicine2014，3，1： | 10 |
| 2 | 显示文摘 | Leonowicz M E Partridge R D | 1998 | Microporous Mesoporous Mater1998，109，117： | 1 |
| 3 | Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial 显示文摘 | Buys SS Partridge E Black A | 2011 | JAMA2011，305，22： | 1 |
| 4 | Characterization and device applications of ZnO films deposited by high power impulse magnetron sputtering (HiPIMS) 显示文摘 | Partridge J G Mayes E L H McDougall N L | 2013 | J Phys D: Appl Phys2013，46，16： | 1 |
| 5 | Detection of rare disseminated tumor cells identifies head and neck cancer patients at risk of treatment failure显示文摘 | Partridge M Brakenhoff R Phillips E | 2003 | Clin Cancer Res2003，9，14： | 1 |
| 6 | Effect of screening on ovarian cancer mortality:the Prostate,Lung,Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial显示文摘 | Buys SS Partridge E Black A | 2011 | JAMA2011，305，22： | 1 |
| 7 | Cene cassettes and cassette arrays in mobile resistance integrons显示文摘 | Partridge SR Tsafnat G Coiera E | | 0，，： | 1 |
| 8 | Effect of screening on ovarian cancer mortality:the Prostate,Lung,Colorectal and Ovarian(PLCO)Cancer Screening Randomized Controlled Trial显示文摘 | Buy S S Partridge E Black A | 2011 | JAMA2011，305，22： | 1 |
| 9 | The interaction between FOXO and SIRT1:tipping the balance towards survival显示文摘 | GIANNAKOU M E PARTRIDGE L | 2004 | Trends Cell Biol2004，14，8： | 1 |
| 10 | Lower Pliocene hominid remains from Sterkfontein 显示文摘 | Partridge T C Granger D E Caffee M W Clarke R J | 2003 | Science2003，300，5619： | 1 |
| 11 | Adherence to initial adjuvant anastrozole therapy among women with early- stage breast cancer 显示文摘 | Partridge AH LaFountain A Mayer E | 2008 | J Clin Oncol2008，26，4： | 1 |
| 12 | Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology显示文摘 | Michelle J Khan Edward E Partridge Sophia S Wang | 2005 | Cancer2005，104，1： | 1 |
| 13 | Gene cassettes and cas- sette arrays in mobile resistance integrons 显示文摘 | Partridge SR Tsafnat G Coiera E | 2009 | FEMS Microbiol Rev2009，33，4： | 1 |
| 14 | A 50 Gb/s IP router显示文摘 | PARTRIDGE C CARVEY P BURGESS E | 1998 | IEEE/ACM Transaction on Networking1998，6，3： | 1 |
| 15 | Ovarian cancer screening in the prostate, lung, coloreetal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial 显示文摘 | Buys SS Partridge E Greene MH | 2005 | Am J Obstet Gynecol2005，193，5： | 1 |
| 16 | Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial 显示文摘 | Greene MH Buys SS Partridge E | 2005 | Am J Obstet Gynecol2005，193，5： | 1 |
| 17 | 3D reinforcement of stiffener-to skin T-joints by z pinning and tufting 显示文摘 | Carrie D D R Dell'Anno G Poulin E Partridge I K | 2006 | Engineering Fracture Mechanics2006，73，： | 1 |
| 18 | Cervical cancer screening 显示文摘 | Partridge E E Abu-Rustum N Giuliano A | 2014 | J Natl Compr Canc Netw2014，12，3： | 1 |
| 19 | 早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择:依据 ASCO 对 CCO临床实践指南的改编显示文摘目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。 | Neelima Denduluri Mark R Somerfield Andrea Eisen Jamie N Holloway Arti Hurria Tari A King Gary H Lyman Ann H Partridge Melinda L Telli Maureen E Trudeau Antonio C Wolff 本刊编辑部 | 2016 | 中国全科医学2016，19，18： | 1 |
| 20 | Results from four rounds of ovarian cancer screening in a randomized trial显示文摘 | Partridge E Kreimer AR Greenlee RT | 2009 | Obstet Gynecol2009，113，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员